ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/cell-therapy
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/cell-therapy
27
trial(s) found.
NCT06577025
Haem
Phase 2
Recruiting
A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination With Daratumumab SC (Tal-D) and Teclistamab SC in Combination With Daratumumab SC (Tec-D) Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants With Standard-risk Newly Diagnosed Multiple Myeloma (
aMMbition
)
anti-CD38 monoclonal antibody
autologous CAR-T-cell therapy,BCMA-targeting
bispecific T-cell engager,BCMA-targeting
bispecific T-cell engager,GPRC5D-targeting
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
NCT06550895
Haem
Phase 2
Recruiting
A Phase 2, Open-Label, Multicenter Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma (
MonumenTAL-8
)
autologous CAR-T-cell therapy,BCMA-targeting
bispecific T-cell engager,GPRC5D-targeting
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT06539338
Haem
Phase 1
Recruiting
A Two-Part Open Label Phase 1 Multicentre Study Evaluating the Safety of INT2104 Infusions in Female and Male Participants Aged 18 Years of Age and Older with Refractory/Relapsing B-cell Malignancies (
INVISE
)
allogeneic CAR-T/NK-cell therapy,CD20-targeting
Leukaemia
Lymphoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06528301
Haem
Phase 1
Recruiting
A Phase 1, Multicenter, Open-label Study of UB-VV111 in Combination With Rapamycin in Relapsed/Refractory (R/R) CD19+ B-cell Malignancies (
UB-VV111-01
)
gene therapy,CAR-T-cell generating,CD19-targeting
+ CAR-T-cell therapy
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Lymphoma
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
NCT06514794
Paed
Phase 2
Recruiting
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in Patients With Relapsed/Refractory Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-RRex) (
WUC007-03
)
allogeneic CAR-T-cell therapy,CD7-targeting
Lymphoma
T-cell acute lymphoblastic leukaemia/lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3052 - Parkville - Royal Children's Hospital Melbourne
NCT06492304
Haem
Phase 1
Recruiting
A Phase 1/2 Dose Evaluation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX131) in Adult Subjects With Relapsed/Refractory Hematologic Malignancies (
CRSP-ONC-008
)
allogeneic CAR-T-cell therapy,CD70-targeting
Acute myeloid leukaemia
B-cell lymphoma
T-cell lymphoma
VIC
3002 - East Melbourne - Epworth Freemasons
NCT06486051
Haem
Phase 2
Recruiting
A Phase 2 Trial to Evaluate the Efficacy and Safety of WZTL-002 in Patients With Relapsed or Refractory Large B-cell Lymphoma (
ENABLE-2
)
autologous CAR-T-cell therapy,CD19-targeting
Diffuse large B-cell lymphoma
Non-Hodgkin's lymphoma
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT06325748
Haem
Phase 1
Recruiting
SENTI-202-101
: A Phase 1, Multicenter, Open-Label Study of SENTI-202, a Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy, in Subjects With CD33 and/or FLT3 Expressing Malignancies
allogeneic CAR-NK-cell therapy,CD33/FLT3-targeting
Haematological malignancy
Myelodysplastic syndrome
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06267729
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II Open Label Study to Evaluate the Safety, Cellular Kinetics, and Efficacy of AZD0754, a Chimeric Antigen Receptor (CAR) T-cell Therapy Directed Against STEAP2, in Adult Participants With Metastatic Prostate Cancer:
APOLLO
allogeneic CAR-T-cell therapy,STEAP2-targeting
Prostate cancer
VIC
3002 - East Melbourne - Epworth Freemasons
NCT06079164
Haem
Phase 1
Recruiting
A Phase 1 Open-label, Single Arm, Multicenter Study Evaluating the Safety and Efficacy of KITE-197 in Subjects With Relapsed or Refractory Large B-cell Lymphoma (
KT-US-656-0601
)
autologous CAR-T-cell therapy,CD19-targeting
Diffuse large B-cell lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
NCT05784441
Haem
Phase 1
Recruiting
A Phase 1b Multicenter, Open-Label, Study of JNJ-90009530, an Autologous Anti-CD20 CAR-T Cell Therapy in Adult Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (
90009530LYM1001
)
autologous CAR-T-cell therapy,CD20-targeting
Non-Hodgkin's lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
NCT05759728
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2a, Multicenter, Open-Label, Dose Escalation and Expansion Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Adult Subjects With Metastatic Colorectal Cancer (
CNA3103-001
)
autologous CAR-T-cell therapy,LGR5-targeting
Colorectal adenocarcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT05727904
Advanced
Phase 3
Recruiting
A Phase 3, Multicenter, Randomized, Open-label, Parallel Group, Treatment Study to Assess the Efficacy and Safety of the Lifileucel (LN-144, Autologous Tumor Infiltrating Lymphocytes [TIL]) Regimen in Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy in Participants With Untreated, Unresectable or Metastatic Melanoma (
IOV-MEL-301
)
anti-PD-1 monoclonal antibody
autologous tumor-infiltrating lymphocytes therapy
+ cell therapy
Melanoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05666700
Haem
Phase 1
Recruiting
CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring Study (
CARAMEL
)
CAR-T-cell therapy
CAR-T-cell therapy,BCMA-targeting
Ciltacabtagene Autoleucel
autologous CAR-T-cell therapy
autologous CAR-T-cell therapy,BCMA-targeting
cancer therapy
cancer therapy,BCMA-targeting
cell therapy
+ CAR-T-cell therapy
Multiple myeloma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT05643742
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Subjects With Relapsed or Refractory B Cell Malignancies (
CRSP-ONC-006
)
allogeneic CAR-T-cell therapy,CD19-targeting
B-cell lymphoma
B-cell malignancy
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Follicular lymphoma
Mantle cell lymphoma
Marginal zone lymphoma
Non-Hodgkin's lymphoma
Small Lymphocytic Lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3004 - Melbourne, Southbank - Alfred Health
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05605899
Haem
Phase 3
Recruiting
An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel Versus Standard of Care Therapy as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (
ZUMA-23
)
autologous CAR-T-cell therapy,CD19-targeting
Diffuse large B-cell lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
NCT05257083
Haem
Phase 3
Recruiting
A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (
CARTITUDE-6
)
anti-CD38 monoclonal antibody
autologous CAR-T-cell therapy,BCMA-targeting
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05201781
Haem
Phase 4
Recruiting
Long-term Follow-up Study for Participants Previously Treated With Ciltacabtagene Autoleucel (
68284528MMY4002--CR109123
)
autologous CAR-T-cell therapy,BCMA-targeting
Multiple myeloma
NCT04920617
Haem
Phase 2
Recruiting
A Phase 2b, Open-label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of an Immunotherapeutic Treatment DPX-Survivac and Pembrolizumab, With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (
VITALIZE
)
alkylating agent
anti-PD-1 monoclonal antibody
cell therapy,T-cell immunotherapy
Diffuse large B-cell lymphoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3128 - Box Hill - Box Hill Hospital - Eastern Health
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NCT04637763
Haem
Phase 1
Recruiting
A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) (
CB10A
)
allogeneic CAR-T-cell therapy,CD19-targeting
B-cell lymphoma
Lymphoma
Non-Hodgkin's lymphoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3121 - Richmond - Epworth Freemasons Hospital
WA
6000 - Perth - Royal Perth Hospital
NCT04503278
Advanced
Phase 1
Recruiting
Phase I/IIa, First-in-human (FIH), Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of CLDN6 CAR-T With or Without CLDN6 RNA-LPX in Patients With CLDN6-positive Relapsed or Refractory Advanced Solid Tumors (
BNT211-01
)
autologous CAR-T-cell therapy,CLDN6-targeting
mRNA vaccine,CLDN6-targeting
Solid tumour
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT03666000
Haem
Phase 1
Recruiting
Phase 1/1b, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 (Azercabtagene Zapreleucel or "Azer-cel") in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) (
PBCAR0191-01
)
allogeneic CAR-T-cell therapy,CD19-targeting
B-cell acute lymphoblastic leukaemia/lymphoma
Non-Hodgkin's lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2170 - Liverpool - Liverpool Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT03601442
Paed
Available
Managed Access Program (MAP) Cohort Treatment Plan
CCTL019B2003I
to Provide Access for Patients With Out of Specification Leukapheresis Product and/or Out of Specification Manufactured Tisagenlecleucel (CTL019; Kymriah®)
autologous CAR-T-cell therapy,CD19-targeting
Acute lymphoblastic leukaemia
Diffuse large B-cell lymphoma
WA
6150 - Murdoch - Fiona Stanley Hospital (AVAILABLE)
ACTRN12625000673448
Haem
Phase 2
Not yet recruiting
Detection of Ultra-High Risk Large B-Cell Lymphoma for Early Delivery of Axicabtagene Ciloleucel: A therapeutic arm of the ALLG NHL34 CLARIFY study (
ALLG-NHL34-DA
)
autologous CAR-T-cell therapy,CD19-targeting
Diffuse large B-cell lymphoma
ACTRN12622001514796
Advanced
Not Applicable
Recruiting
KARPOS
- A Phase 1, Single-Centre, Non-randomised, Open-labelled, Escalating Dose Study of Autologous GD2-Specific Chimeric Antigen Receptor-expressing Peripheral Blood T cells in Patients with Recurrent GD2-positive Glioblastoma Multiforme
Bevacizumab
CAR-T-cell therapy
CAR-T-cell therapy,GD2-targeting
Cyclophosphamide
Fludarabine
GD2-iCAR-PBT
Ifosfamide
alkylating agent
anti-VEGF monoclonal antibody
antimetabolite
autologous CAR-T-cell therapy
autologous CAR-T-cell therapy,GD2-targeting
cancer therapy
cancer therapy,GD2-targeting
cancer therapy,VEGF-targeting
cell therapy
cytotoxic chemotherapy
immuno-oncology therapy,VEGF-targeting
+ CAR-T-cell therapy
Glioblastoma
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
ACTRN12622000675729
Paed
Not Applicable
Recruiting
A Phase I Study of the Safety of Autologous GD2-Specific Chimeric Antigen Receptor-Expressing T Cells in Children with Diffuse Midline Glioma (
LEVI’S-CATCH
)
Bevacizumab
CAR-T-cell therapy
CAR-T-cell therapy,GD2-targeting
Cyclophosphamide
Fludarabine
GD2-iCAR-PBT
Radiotherapy
alkylating agent
anti-VEGF monoclonal antibody
antimetabolite
autologous CAR-T-cell therapy
autologous CAR-T-cell therapy,GD2-targeting
cancer therapy
cancer therapy,GD2-targeting
cancer therapy,VEGF-targeting
cell therapy
cytotoxic chemotherapy
immuno-oncology therapy,VEGF-targeting
+ CAR-T-cell therapy
Central nervous system cancer
Diffuse intrinsic pontine glioma
Diffuse midline glioma
High-grade glioma
NSW
2031 - Randwick - Prince of Wales Hospital
ACTRN12621000762853
Haem
Phase 1
Recruiting
Phase I Clinical Trial of MB.CART19.1 CD19 Chimeric Antigen Receptor (CAR) T Cells in Relapsed or Refractory CD19-Positive Haematological Malignancy
autologous CAR-T-cell therapy,CD19-targeting
B-cell malignancy
Leukaemia
Non-Hodgkin's lymphoma
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (25)
Not yet recruiting (1)
Recruitment Country and State
VIC (20)
NSW (14)
QLD (6)
WA (5)
SA (4)
NZ (2)
Phase
Phase 1 (11)
Phase 1 / Phase 2 (3)
Phase 2 (6)
Phase 3 (3)
Phase 4 (1)
Trial Type
Haem (19)
Advanced (5)
Paed (3)
Cancer Therapy Class
CD19
37%
BCMA
19%
CD20
15%
CD38
7%
GPRC5D
7%
cereblon
7%
proteasome
7%
PD-1
7%
PD-1/PD-L1
7%
GD2
7%
VEGF
7%
mTOR
4%
mTORC1
4%
mTORC2
4%
CD7
4%
CD70
4%
CD33
4%
FLT3
4%
STEAP2
4%
LGR5
4%
CLDN6
4%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (11)
2050 - Camperdown - Chris O'Brien Lifehouse (8)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (6)
3004 - Melbourne, Southbank - Alfred Health (5)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (5)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (4)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (3)
3002 - East Melbourne - Epworth Freemasons (3)
6150 - Murdoch - Fiona Stanley Hospital (3)
3065 - Fitzroy - St Vincent's Hospital Melbourne (2)
3052 - Parkville - Royal Children's Hospital Melbourne (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
3168 - Clayton - Monash Medical Centre (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
4120 - Greenslopes - Greenslopes Private Hospital (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
NZ.0622 - Takapuna - North Shore Hospital (1)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (1)
3121 - Richmond - Epworth Freemasons Hospital (1)
6000 - Perth - Royal Perth Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
2031 - Randwick - Prince of Wales Hospital (1)
Cancer Type
Cancer
Haematological malignancy
Lymphoma
Non-Hodgkin's lymphoma
B-cell malignancy
B-cell lymphoma
Mature B-cell malignancy
Leukaemia
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Solid tumour
Multiple myeloma
Plasma cell disorder
Lymphoid leukaemia
Acute lymphoblastic leukaemia
Chronic lymphocytic leukaemia
Central nervous system cancer
Glioma
High-grade glioma
Malignant glioma
Neurological cancer
T-cell acute lymphoblastic leukaemia/lymphoma
Acute myeloid leukaemia
Myeloid leukaemia
T-cell lymphoma
Myelodysplastic syndrome
Myeloproliferative neoplasm
Male genital cancers
Prostate cancer
Urogenital cancer
Colorectal adenocarcinoma
Colorectal cancer
Gastrointestinal cancer
Lower gastrointestinal cancer
Melanoma
Follicular lymphoma
Mantle cell lymphoma
Marginal zone lymphoma
Small lymphocytic lymphoma
B-cell acute lymphoblastic leukaemia/lymphoma
Glioblastoma
Diffuse intrinsic pontine glioma
Diffuse midline glioma
H3K27M-mutant glioma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy